ClinicalTrials.gg
RecruitingNCT06905561Updated Apr 3, 2026

Topical Diclofenac for Prevention of Radiation-induced Dermatitis

An interventional study of Diclofenac Sodium Gel and Placebo gel in Head and Neck Tumor and Breast Cancer, sponsored by The Second Affiliated Hospital of Hainan Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by The Second Affiliated Hospital of Hainan Medical University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 175 studies in Head and Neck Neoplasms with a site in China — 88 open to participants now, 97 under way, 12 of them phase 3. Head and Neck Neoplasms · China.

Planned enrollment
49th of 147
156 · median 84
Started
2025
with 16 others
No phase
18 of 175
8 open now
Primary completion
2026-06
later than 29 of 96 live
Registered
122nd of 175
by date

Among the 175 studies in Head and Neck Neoplasms with a site in China, this one is the 49th largest by planned enrollment of the 147 interventional ones that give a count, is one of 17 that started in 2025, is one of 18 with no phase, reaches primary completion later than 29 of the 96 other live ones, and was the 122nd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

88 of the 175 studies in Head and Neck Neoplasms with a site in China are open now. Recruiting first, the newest first:

83 more — sign in →

All 88 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Head and Neck Neoplasms with a site in China, or all of them as a file.
02

Study summary

Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy. The main pathways of RID is inflammation and oxidative stress on local and systemic bases. The Diclofenac is a COX-2 inhibitor and Nonsteroidal anti-inflammatory drugs whose anti-inflammatory and antioxidant activities have been proven in several clinical trials. Thus, the aim of the present study is to evaluate the efficacy of Diclofenac sodium gel as a prophylactic method against the development of RID.

Read the detailed description

Radiation induced dermatitis (RID) is one of the most commonly reported adverse events of Head and neck tumor, breast cancer radiation therapy (RT). Radiation therapy toxicity is exhibited within hours to weeks of exposure and persisting throughout the course of treatment. Radiation induced dermatitis is a result of generation of reactive oxygen species (ROSs), which in return induces epidermal and dermal inflammatory responses. Radiation causes structural tissue damage, which trigger production of pro-inflammatory mediators; as NF-κB, COX-2, and cytokines such as IL-6, TNF-a, and IFN- γ. Subsequently erythema, ulceration, and edema are developed,then followed by thinning of the epidermis, dry desquamation. If damage is more severe, moist desquamation occur. It can be deduced that inflammatory response plays a significant role in the radiotherapy induced dermatitis.

There are many agents that are used in the management of RID in the clinical settings, however, up till now there is none supported by the guidelines. Radiation induced dermatitis occurrence, not only could it impair the patient's quality of life but it could also affect the RT course of treatment, which could negatively influence the cancer treatment. Therefore more effort is needed to find a method of prevention of RID, resulting from Head and neck tumor,breast cancer RT.

Diclofenac sodium gel, a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (non-NSAID), is widely used to treat inflammatory conditions, and studies show that topical diclofenac has no safety concerns. It has been used for more than 20 years in patients with osteoarthritis without any significant adverse effects. The combination of diclofenac sodium as a COX-2 inhibitor and ionising radiation not only enhances the effect of radiation on tumour cells, but also improves radiation therapy for patients. Studies have shown that diclofenac sodium gel, through COX-2, can be used to prevent the development of capecitabine-induced hand-foot syndrome (HFS). RID upregulates COX-2 due to inflammatory stimulation, and COX-2 indirectly produces reactive oxygen species (ROS). The investigators conclude that diclofenac gel can reduce ROS by locally inhibiting COX-2 enzyme, thus preventing radiation dermatitis and reducing skin damage. Therefore, the investigators plan to conduct a study on the use of diclofenac sodium gel in radiation dermatitis to investigate the incidence of RID grade 2 and above at different time points after radiotherapy in patients with head and neck tumours, and whether it can reduce the incidence and severity of RID-related symptoms.

03

Conditions studied

  • Head and Neck Tumor
  • Breast Cancer

Keywords

  • Topical Diclofenac
  • Radiation-induced dermatitis
  • Prevention
  • Head and Neck tumor
  • Brest Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female which are 18 years of age or older
  2. Performance status \< 2
  3. Epithelial carcinoma of oropharynx, nasopharynx, larynx, hypopharynx, paranasal sinus and salivary glands or breast cancer, planned to receive a total dose of at least 50 Gy
  4. The RTOG radiation dermatitis rating should be equal to 0 and the skin nutrition should be good
  5. The main organs are functioning normally and meet the following standards: (1) Blood routine examination must meet the following criteria: (no blood transfusion within 14 days) a. HB ≥ 100g/L, b. WBC ≥3×10\^9/L c. ≥1.5×10\^9/L, d. ≥100×10\^9/L; (2) Biochemical examination must meet the following standards: a. BIL\<1.5 times the value (ULN), b. and AST\<2.5ULN, GPT ≤1.5×ULN; c. Serum Cr≤1 ULN, endogenous rate>60ml/min (Cockcroft Gault formula);(3).Good coagulation function: defined as International standardized ratio () or prothrombin time (PT) ≤1.5×ULN;(4).The myocardial enzyme spectra were in the normal range.
  6. Patients willing and able to give signed and, in the opinion of the Investigator, to comply with the Clinical Investigation Plan tests and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women
  2. A known history of intolerance or allergy to any component of the product;
  3. severe cardiopulmonary disease (such as unstable angina attacks, grade II cardiac insufficiency, acute myocardial infarction, acute episodes of , pulmonary heart disease);
  4. The acute phase is accompanied by inflammatory skin diseases, such as atopic dermatitis, contact dermatitis, psoriasis, lichen planus, pityriasis rosea.
  5. Systemic diseases known to delay the skin healing process, such as diabetes or severe kidney failure;
  6. Skin rupture caused by malignant tumors.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Treatment group(diclofenac sodium gel )

    In addition to routine skin care, diclofenac sodium gel was applied to the skin of the irradiated site triple a day a day from the date of first radiotherapy until end of radiotherapy or until the test side skin developed ≥grade 3 RID.Conventional health care:Minimize skin irritation, friction and excessive sun exposure in the irradiated area (level III to IV evidence), avoid wearing high-neck and tight clothing, and recommend low-neck tops. Subjects wash irradiated skin with water or wet towel, and wipe skin with dry towel to keep irradiated skin clean and dry.

    Drug: Diclofenac Sodium Gel

  • Placebo comparator
    control group(Placebo Comparator)

    In addition to routine skin care, Placebo gel was applied to the skin of the irradiated site triple a day a day from the date of first radiotherapy until end of radiotherapy or until the test side skin developed ≥grade 3 RID.Conventional health care:Minimize skin irritation, friction and excessive sun exposure in the irradiated area (level III to IV evidence), avoid wearing high-neck and tight clothing, and recommend low-neck tops. Subjects wash irradiated skin with water or wet towel, and wipe skin with dry towel to keep irradiated skin clean and dry.

    Other: Placebo gel

Interventions

  • Diclofenac Sodium Gel were applied to the skin of the irradiated site triple a day a day from the date of first radiotherapy until end of radiotherapy or until the test side skin developed ≥grade 3 RID.

  • OtherPlacebo gel

    The placebo does not contain the active ingredients of Jalosome, only the co-formulants.

06

What researchers measure

Primary outcomes

  1. Incidence of development of grade ≥ 2 RID

    If the patient developed grade ≥ 2 RID or not, RTOG standards were used for evaluation

    Time frame: From the first day of radiotherapy until 2 weeks after the end of radiotherapy

Secondary outcomes

  1. Evaluation of Time to develop grade ≥2 RID

    EvaluationTime to develop grade ≥ 2 RID incidence, will be assessed by RTOG criteria based on the clinical presentation of Time to develop grade ≥2 RID

    Time frame: From the first day of radiotherapy until 2 weeks after the end of radiotherapy

  2. Evaluation of Pain Intensity

    Pain related assessment will be done through a Visual Analog Scale, with 0 being No pain and 10 being unbearable pain

    Time frame: From the first day of radiotherapy until 2 weeks after the end of radiotherapy

  3. Evaluation of Incidence of Treatment-Emergent Adverse Events

    Patients will be educated and instructed to report any adverse events

    Time frame: From the first day of radiotherapy through treatment completion(up to 7 weeks or 5 weeks)

  4. Evaluation of Quality of life

    Skin-related quality of life assessed through the Dermatology Life Quality Index (DLQI)

    Time frame: From the first day of radiotherapy until 2 weeks after the end of radiotherapy

  5. Incidence of radiotherapy interruption

    If the patient has been interrupted by RID or not

    Time frame: From the first day of radiotherapy through treatment completion (up to 7 weeks or 5 weeks)

  6. The Concentration of inflammatory factors (IL-2、IL-4 、IL-6、IL-10、interferon-γ、TNF-α)

    The differences in expression of inflammatory factors, such as IL-2 (pg/ml),IL-4 (pg/ml),IL-6 (pg/ml),IL-10 (pg/ml),interferon-γ(pg/ml) and TNF-α(pg/ml).

    Time frame: Baseline(Day 0) and through study completion(Day 36 or Day 46)

  7. The Concentration of inflammatory factors (WBC)

    The differences in expression of inflammatory factors, such as WBC(10\^9/L).

    Time frame: Baseline(Day 0) and through study completion(Day 36 or Day 46)

  8. The Concentration of inflammatory factors (CRP)

    The differences in expression of inflammatory factors, such as CRP(mg/L).

    Time frame: Baseline(Day 0) and through study completion(Day 36 or Day 46)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2026, 16 months after the start.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 16 months is below that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Apr 1, 2025
StartActual
Feb 13, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Aug 31, 2026
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06905561
Lead sponsor
The Second Affiliated Hospital of Hainan Medical University
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
Feb 13, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Apr 3, 2026

Study contacts

yuecan zeng
Contact
wellyy2005@hainmc.edu.cn
19946610752
junnv xu
Contact
xujunnv@sina.com
18208946196

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac Sodium Gel

Start the discussion